MRC1 and neoplasm: Deficiency in MMR genes is often associated with an immune-rich microenvironment, with high CD8 and T-lymphocyte infiltration, which promotes an effective antitumor response and explains the benefits of immune checkpoint blockade regardless of tumor location, particularly anti-PD-1/PD-L1 inhibitors [57,58,59].